Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,256 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Triptans Clear all

Conditions: Leukemia
Interventions: filgrastim, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, mitoxantrone, Asparaginase, prednisone, thioguanine, vincristine, radiation therapy, allopurinol, bactrim; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 64 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 78
States / cities: Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more

Conditions: Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis
Interventions: Ivermectin; Drug
Lead sponsor: Patrick Robinson; Other
Eligibility: 12 Years to 110 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Antonio, Florida

Conditions: Diffuse Large B Cell Lymphoma, DLBCL, Cancer
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim; Drug · Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 70 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants With Lower-than-average Mental Well-being
Interventions: Psilocybin, Context 1, Context 2, Placebo; Drug · Behavioral
Lead sponsor: Robin Carhart-Harris, PhD, MA; Other
Eligibility: 21 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stroke, Acute, Ischemic Stroke
Interventions: Melatonin; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Brain Tumors, Central Nervous System Tumors
Interventions: carboplatin, lomustine, procarbazine hydrochloride, thioguanine, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 9 Years
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2012
U.S. locations: 179
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 141 more

Conditions: Leukemia, Multiple Myeloma
Interventions: CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan; Drug
Lead sponsor: Sally Arai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma, Stage I Retinoblastoma, Unilateral Retinoblastoma
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Examination Under Anesthesia, Magnetic Resonance Imaging, Melphalan, Ultrasound Biomicroscopy, Vincristine; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more

Conditions: Neutropenia, Sarcoma
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, topotecan hydrochloride, vincristine sulfate, conventional surgery, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 35 more

Conditions: Migraine, Pain, Nausea, Vomiting, Aura
Interventions: Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule, Arm 4: Promethazine HCl 18.75 mg, Arm 5: Promethazine HCl 37.5 mg, Placebo; Drug · Other
Lead sponsor: Charleston Laboratories, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: New Port Richey, Florida • North Miami Beach, Florida • Greer, South Carolina

Conditions: Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia
Interventions: Clofarabine, Cytarabine, Dexamethasone, Idarubicin, Rituximab, Sorafenib, Sorafenib Tosylate, Vincristine, Vincristine Sulfate; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, T-Cell, Peripheral
Interventions: Denileukin diftitox, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 42 more

Conditions: Mantle Cell Lymphoma
Interventions: Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Tobacco Use Disorder
Interventions: Psilocybin, Niacin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • New York, New York

Conditions: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome; Procedure · Drug · Radiation + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 169
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more

Conditions: Low Grade Glioma
Interventions: Vinblastine, Bevacizumab; Drug
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 6 Months to 18 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more

Conditions: Lung Cancer
Interventions: topotecan hydrochloride, vinorelbine tartrate; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 120 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Migraine Disorders
Interventions: Placebo, Combination Product (sumatriptan succinate/naproxen sodium); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more

Conditions: Leukemia, Lymphoma
Interventions: cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 15 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2006
U.S. locations: 23
States / cities: La Jolla, California • San Francisco, California • Wilmington, Delaware + 18 more

Conditions: Prostate Cancer
Interventions: paclitaxel, vinorelbine tartrate; Drug
Lead sponsor: James Ahlgren; Other
Eligibility: 18 Years to 120 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Docetaxel, CPT-11, Paclitaxel, Vinorelbine Tartrate, Gemcitabine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 4
States / cities: West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Healthy
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma, Lymphoma, B-Cell
Interventions: Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq; Drug · Device
Lead sponsor: Jennifer Amengual; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Search by objective public record fields.

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19

Split-Dose R-CHOP for Older Adults With DLBCL

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

Melatonin in Acute Stroke

Combination Chemotherapy in Treating Children With Progressive Brain Tumors

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

Persisting Effects of Psilocybin

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)